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Abstract 
 
Objective 
 
The objective of this selective EBM review is to determine whether or not pharmacologic 
therapy for blood pressure control effective at reducing symptoms and improving quality of life 
in patients with postural orthostatic tachycardia syndrome (POTS). 
 
Study Design 
 
Systematic review of two single blind crossover randomized control trials published in 2009 and 
2012 and one retrospective case control study published in 2009. 
 
Data Sources 
 
Three studies were obtained using PubMed. 
 
Outcomes Measured 
 
Self reported symptoms of POTS and the Vanderbilt POTS symptom scoring system as well as 
quality of life in patients. 
 
Results 
Raj et al. (2009), Coffin et al. (2012), and Lai et al. (2009) all demonstrated improvement in 
symptoms and quality of life with blood pressure altering medications in patients with POTS. 
Conclusion 
 
Evidence to support effective treatment for symptom relief and quality of life improvement it 
patients with POTS is scarce in the current literature.  This systematic review indicates that 
evidence is strong for efficacy of β-blockers and DDAVP to control standing HR and improve 
overall symptom burden in POTS patients compared to placebo and other treatment modalities.  
Future studies comparing the control of catecholamines vs β-adrenergic blockade in POTS 
would be beneficial for the understanding of underlying mechanisms, therefore provide better 
control of symptoms in patients 
 
Key Words 
 
Postural orthostatic tachycardia syndrome, POTS, beta blockers 
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Introduction 
Postural orthostatic tachycardia syndrome (POTS) is a disorder of chronic orthostatic 
intolerance that occurs in patients who experience symptoms in response to postural change.1  
POTS is a disorder of the autonomic nervous system hallmarked by an excessive increase in 
heart rate  in response to postural stress without an associated drop in blood pressure.2  POTS is 
clinically defined as an increase in heart rate by ≥ 30 bpm in adults, by ≥ 40 bpm in children, or 
an absolute heart rate exceeding 120 bpm, within 10 minutes of assuming an upright posture, 
with no corresponding orthostatic fall in blood pressure.3,4  Patients with postural orthostatic 
tachycardia syndrome most commonly report clinical symptoms of dizziness, weakness, fatigue, 
mental clouding, blurred vision, palpitations, tremulousness, and anxiety.1,3,5  POTS is associated 
with a poor quality of life and has been found to have the functional impairment similar to 
patients who have congestive heart failure or chronic obstructive pulmonary disease.1,4  Although 
the exact cause of this disorder is not entirely understood, there are a few theories for the 
underlying mechanisms that lead to orthostatic instability.  Hypovolemia caused by an 
impairment of the renin-angiotensin-aldosterone system is thought to play a major role in the 
disorder.  Several studies in patients with POTS have noted observations of hypovolemia, 
reduced RBC volume, and excessive venous pooling as evidence of a decrease or redistribution 
of blood volume.5  Other theories include decreased venous return, cardiovascular 
deconditioning, a primary abnormality in the baroreflex, and increased sympathetic activity 
(including elevated arterial NE levels at rest and decreased NE clearance).5  
POTS is estimated to affect 500,000 Americans and is disproportionately observed in 
women of childbearing age.1,2  Patients with POTS present at a relatively young age (15-45 
years) and the disorder is becoming increasingly recognized in adolescents.  The exact amount of 
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healthcare spending contributed to POTS is unknown, however the condition contributes to 
worsened physical health, bodily pain, and physical and social functioning in the younger 
population.  The population affected and the lack of standardized treatment modalities 
contributes to the importance of recognition of POTS in the clinical setting. 
No known cure or optimal therapy exists for postural orthostatic tachycardia syndrome.3  
Because many patients with POTS have a low plasma volume, most patients respond rapidly and 
have symptomatic improvement with saline infusion.5  It is common practice for practitioners to 
advise patients to follow a high sodium diet of 200-300 mEq/day with a significant increase in 
water consumption, restrict caffeine, and gradually increase exercise.2,3,5  In addition to dietary 
and lifestyle changes, many patients are prescribed medication to either increase plasma volume, 
increase peripheral vasoconstriction, or compensate for increased catecholamine levels.  
Midodrine, beta-blockers, SSRIs, and fludrocortisone are medications that are frequently 
prescribed to POTS patients depending on the evaluation of their symptoms.3  Given that the 
hallmark symptom and diagnostic sign of POTS is tachycardia, β-adrenergic blockade is shown 
to be a logical treatment to reduce symptoms in patients.1  This review paper examines the 
effectiveness in blood pressure control and fluid retention with pharmacologic therapy to reduce 
tachycardia, thus reducing symptoms and improving the quality of life in patients with POTS.        
 
Objective 
The objective of this selective EBM review is to determine whether or not pharmacologic 
therapy for blood pressure control is effective at reducing symptoms and improving quality of 
life in patients with postural orthostatic tachycardia syndrome (POTS). 
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Methods 
This review is comprised of two single blind crossover randomized control trials and one 
retrospective case control study that meet specific criteria for the comparison of pharmacologic 
therapy for blood pressure control to reduce symptoms and improve quality of life in patients 
with postural orthostatic tachycardia syndrome.  The first study utilized propranolol as a method 
of blood pressure control and symptomatic relief from POTS.  The second study measured the 
outcomes on symptoms by using desmopressin to improve fluid status.  The third study was a 
retrospective case control study that compared the relief of symptoms in patients treated with 
medications, most commonly β-blockers or midodrine.  All patients used for this review met the 
clinical diagnostic criteria for postural orthostatic tachycardia syndrome and did not have 
additional comorbid conditions that could impact orthostatic intolerance. 
Key words used in the research of these included studies were postural orthostatic 
tachycardia syndrome, POTS, beta blockers, and treatment.  All articles used in this systematic 
review were published articles in English from peer-reviewed journals and located via PubMed.  
Articles had to meet several inclusion criteria such as: relevance to the proposed research 
question, relationship to patient oriented evidence that matters (POEMs), at least two randomized 
control trials, and original research published in the year 2000 or later.  Exclusion criteria 
included articles published prior to the year 2000, articles focused on disease oriented outcomes 
(DOEs), and systematic review articles.  Statistics reported in the articles utilized in this study 
include p-values.  Numbers needed to treat (NNT), relative benefit increase (RBI), and absolute 
benefit increase (ABI) were calculated and reported for the Lai3(2009) study to determine results 
as a POEM.  Table 1 demonstrates the demographics and characteristics of studies included in 
this systematic review. 
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Table 1 - Demographics & Characteristics of included studies  
Study Type # 
PT
s 
Age  Inclusion Criteria Exclusion 
Criteria 
W/
D 
Interventions 
Raj1 
(2009) 
Single 
blind RCT 
54 >18 
years 
old 
PTs meting the criteria 
for POTS 
• < 18 years 
old 
• Use of 
Fludrocortis
one within 5 
days 
0 • Protocol 1: 
propranolol 20 
mg D (low 
dose) 
• Protocol 2: 
propranolol 80 
mg D (high 
dose) 
 
Coffin2 
(2012) 
Single 
blind RCT 
30 >18 
years 
old 
• Patients referred to 
the Vanderbilt 
University 
Autonomic 
Dysfunction Center 
PTs meeting criteria 
for POTS 
• >/= 6 months of 
symptoms 
 
• < 18 years 
old 
 
0 • Desmopressin 
(DDAVP) 0.2 
mg D 
Lai3(200
9) 
Retrospecti
ve case 
control 
study 
47 11-
17 
years 
• Adolescents with 
POTS seen at Mayo 
Clinic from 2002-
2005 
• > 18 years 
old 
13 • Beta blockers 
vs Midodrine 
 
Outcomes Measured 
The first two studies measured outcomes using self reported symptoms and the 
Vanderbilt POTS symptom scoring system: POTS symptoms including mental clouding, blurred 
vision, shortness of breath, rapid heart beat, tremulousness, chest discomfort, headache, 
lightheadedness, and nausea immediately before and at 2 and 4 hours post therapy.  Patients were 
asked to rate severity of the 9 symptoms on a scale 0-10 with 0 being absence of symptom.  The 
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sum of the scores at each interval during the study was used to calculate total symptom burden.  
The third study measured outcomes using the Walker Functional Disability Inventory to asses for 
a change in quality of life prior to and after treatment with 15 questions to rate activity.  Patients 
were asked to rate their activity before treatment at the Mayo Clinic and level of activity at the 
time of the survey.  The scale rated activities from 0 (no trouble performing activity) to 4 
(impossible to perform the activity).  The sum of scores was added up to calculate quality of life 
from 0 (no disability) to 60 (inability to function). 
 
Results 
The Raj1(2009) study, a single-blind RCT, compared a low dose of 20 mg propranolol vs 
placebo in POTS patients to measure symptom burden immediately before and at 2 and 4 hours 
post drug administration.  The study included patients referred to the Vanderbilt University 
Autonomic Dysfunction Center with POTS between November 2003 and September 2008.  
Patients met the diagnostic criteria for POTS and had at least 6 months of symptoms and were at 
least 18 years of age.  Exclusion from the study included patients with existing comorbid 
conditions, taking medications that could alter autonomic tone, and the administration of 
fludrocortisone within 5 days of testing.  Patients were predominately female with a mean age of 
34 years.  There was no difference in symptoms scores at baseline between the propranolol and 
placebo groups.1  The decrease in total symptom burden was shown to be significant greater with 
20 mg propranolol from baseline to 2 hours post treatment (p = 0.044).  At 4 hours post 
treatment, symptom burden was significantly lower after administration of propranolol vs 
placebo (p = 0.045).  The study revealed that propranolol decreased each component symptom of 
the Vanderbilt POTS symptom score more than placebo.1  The study also revealed that there was 
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no significant difference between low dose (20mg) and high dose (80 mg) of propranolol in 
lowering total symptom score, revealing that a low dose is sufficient to improve symptom burden 
of POTS.  This trial was safe and there were no reported adverse effects to treatments.  
 
Table 2. Symptom Score with Propranolol 20 mg and Placebo in POTS patients (n=54) 
Symptom Score Before 2 Hours After 4 Hours After 
Propranolol 20 mg 17 9.5 10 
Placebo 16 15 12.5 
P-Value (between Propranolol 
20mg and placebo) 
0.385 0.012 0.007 
*Values expressed as a group of means 
 
The Coffin2(2012) study, a single-blind RCT, compared 0.2 mg of desmopressin 
(DDAVP) to placebo in POTS patients to measure changes in symptom burden immediately 
before, 2, and 4 hours post drug administration.  The study included patients referred to the 
Vanderbilt University Autonomic Dysfunction Center with POTS between November 2003 to 
September 2008.  Patients met the clinical diagnostic criteria for POTS with at least 6 months of 
symptoms and were at least 18 years of age.  Patients with an existing comorbid condition 
known to cause orthostatic intolerance, on prolonged bed rest, and under 18 years of age were 
excluded from this study.  The study included 30 patients who met the previous criteria, the 
majority female (26) with a mean age of 37 years.  Symptom ratings were similar between the 
DDAVP and placebo prior to treatment (p = 0.99).  Symptom score was significantly better at 2 
hours post treatment for patients treated with DDAVP versus placebo (p < 0.001).2  DDAVP also 
led to a significantly better symptom score at 4 hours post treatment vs placebo (p = 0.006).2  
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There was a significant reduction of palpitation with DDAVP (p = 0.023) and a strong, but not 
statistically significant reduction of visual disturbance with the drug vs placebo (p = 0.086).2  
This study was safe and there were no reported adverse reactions to therapy in either group. 
 
Table 3.  Symptom Score with desmopressin (DDAVP) 0.2 mg vs placebo 
Symptom Score Before 2 Hours Post 4 Hours Post 
DDAVP 0.2 mg 18 ± 18 13 ± 15 13 ± 16 
Placebo 18 ± 17 19 ±16 19 ± 18 
P-value (between DDAVP 
0.2mg and placebo) 
0.587  0.001 0.009 
*Values expressed as means ± standard deviation 
 
The Lai3(2009) study, a retrospective case control study, surveyed POTS patients seen at 
the Mayo clinic and prescribed medication for symptom relief.  The most commonly prescribed 
medications compared in this study were midodrine (n=13) and β-blockers (n=14).  The study 
included patients seen at the Mayo Clinic from 2002 through 2005 for POTS and excluded 
patients over the age of 18.  Patients treated with midodrine vs β-blockers in this study were not 
statistically different in terms of age, gender, and change of baseline heart rate from initial 
evaluation to survey completion.3  On the Walker Functional Disability Inventory (WDFI) 
survey, patients had more functional disability prior to receiving treatment at the Mayo Clinic.  
Initial scores were similar before evaluation at the clinic in patients treated with midodrine vs a 
β-blocker (p = 0.126).3  Patients who were given a β-blocker reported a greater improvement in 
functional ability than patients who were treated with midodrine (p = 0.004).3  When compared 
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to patients who were not given a β-blocker or midodrine, patients in the β-blocker group had a 
significant improvement in their WDFI score (p = 0.046), whereas midodrine compared to the 
same group showed no significant difference.3  This study indicated that overall improvement in 
functional ability and quality of life in patients with POTS appears to be greater when patients 
are treated with a β-blocker.  The absolute benefit increase (ABI) was calculated to be 10.9% in 
patients treated with midodrine or β-blocker compared to other existing treatments for POTS.  
This study also revealed a calculated numbers needed to treat (NNT) of 9.  This study was safe 
and there were no reported adverse effects from medication treatment.  A total of 13 patients 
were lost to follow up during this study. 
 
Table 4. Effects on POTS symptoms in patients treated with Midodrine vs β-Blocker 
Symptoms Midodrine (n=13) β-blocker (n=14) 
Improved 6 8 
Worsened 3 4 
No Change 4 2 
 
Discussion 
This systematic review compared the use of pharmacologic therapy used for blood 
pressure control for the use in patients with POTS to relieve symptoms and improve the quality 
of life in these patients.  Currently, β-blockers are considered in the treatment for POTS patients, 
however there is no gold-standard treatment in existence and patients are treated with a “trial and 
error” approach.  The review of the 3 studies used in this review reveal that β-blockers, including 
propranolol at a low dose of 20 mg daily, show a statistically significant improvement in patient 
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reported symptoms.  Another method of treatment to relieve symptoms in POTS includes 
desmopressin at a low dose of 0.2 mg.  When comparing methods of blood pressure control, it 
was also proven that β-blockers show a more significant improvement than midodrine in the 
relief of patient reported symptoms.  These studies found that medications that have the ability to 
reduce HR can be effective in reducing standing HR and improvement of symptoms in patients 
with POTS.1  Beta-adrenergic blockade is a relatively safe treatment modality to use in patients 
with POTS of the risk profile of the medication class is understood.  Based on side effect profile, 
β-blockers could safely be used in POTS patients without the existence of an additional 
comorbid condition such as heart failure, reactive airway disease, diabetes, or peripheral artery 
disease, as β-adrenergic blockade can all exacerbate these illnesses.  It is also important to note 
the effects of acute withdrawal from β-blockers caused by increased sympathetic activity.  Acute 
withdrawal from the drug could worsen POTS since it is thought to be associated with an 
increased sympathetic tone at baseline.  
Desmopressin as another treatment possibility for POTS patients studied in this review 
shows promising results for reduction in standing HR and improvement of symptoms.  DDAVP 
has a major potential side effect of hyponatremia based on increasing free-water retention.2  
Once daily dosing of desmopressin at a low dose of 0.2 mg did not show any harm in the study, 
however practitioners should be cautious to prescribe DDAVP as a daily medication in POTS 
patients due to the risk of hyponatremia.2  Serum sodium levels should be routinely checked in 
patients taking DDAVP for hyponatremia.  Based on overall evaluation, β-blockade appears to 
be a safer and more effective treatment for symptoms in patients with POTS.   
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Limitations of this systematic review include the lack of research on POTS and effective 
treatment modalities.  A major limitation to consider is that the Raj and Coffin studies were both 
performed at Vanderbilt University, utilizing their scoring system for POTS symptoms.  A short 
follow up time is another limitation to consider concerning 2 of the studies used in this review.  
A 4 hour follow up window makes it difficult to assess and predict the long-term efficacy of the 
treatment modalities studied.  It is also difficult to predict the long-term safety and tolerability of 
β-blockers and DDAVP for the treatment of POTS.1,2  The Coffin study also had a relatively 
small sample of patients.2  The Lai study states that a patient selection bias may have occurred 
because the sample population included only POTS patients willing to take a survey.  These 
patients may have only completed and returned the survey because they had a good experience at 
the Mayo Clinic or actually had improvement of the symptoms.3  The Lai study also had a high 
dropout of patients who participated in the study.  Of the 121 adolescents seen at the Mayo 
Clinic for POTS, only 47 patients returned completed surveys.3  Other limitations of the study 
include the restrictions involved in a retrospective survey, the survey basis on subjective patient 
feedback, and the relatively small sample size.3 
 
Conclusion 
Pharmacologic therapy for blood pressure control is an effective treatment to improve 
symptoms and quality of life in patients with POTS.  Two studies showed evidence in symptom 
improvement compared to placebo and one showed effectiveness of β-blockers over the use 
midodrine.  Two studies indicated that symptom relief occurs as soon as 2 and 4 hours post 
treatment with either a β-blocker or desmopressin.  The Lai study indicated that symptom relief 
and improvement in functional ability also occurs over the longer term with treatments such as 
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β-blockers and midodrine, also revealing that β-blockers are the more effective treatment option 
in POTS patients.  The studies also revealed that the use of low dose propranolol (20 mg) and 
DDAVP (0.2 mg) is safe and shows no concerning adverse effects for the treatment of POTS in 
the absence of comorbidities.   
Due to the relatively small sample size used in these studies and the short follow up time, 
it would be beneficial for future studies to follow patients over a longer period of time to observe 
symptom improvement over the long-term.  This would also be helpful in assessing the safety of 
the treatment modalities for chronic treatment for POTS symptoms.  Future studies could also 
show benefit by comparing multiple treatment options against each other rather than simply 
observing one option compared to a placebo.  Lastly, future studies comparing the control of 
catecholamines vs β-adrenergic blockade in POTS would be beneficial for the understanding of 
underlying mechanisms, therefore provide better control of symptoms in patients.  With the lack 
of research available for the treatment of postural orthostatic tachycardia syndrome, it seems that 
β-adrenergic blockade and DDAVP are safe and effective treatment options for improving 
symptom burden and quality of life in POTS patients. 
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